Antibacterial drug use increases at academic medical centers
Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone. Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name Zevtera.
Full Post: Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections
Antibacterial drug use appears to have increased at academic medical centers between 2002 and 2006, driven primarily by greater use of broad-spectrum agents and the antibiotic vancomycin, according to a report in the Nov. 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Using antibacterial drugs increases the risk that pathogens will become resistant to their effects, according to background information in the article. Infection with drug-resistant bacteria is associated with greater illness and death and higher health care costs than infection with bacteria susceptible to antibiotics. “Many professional societies and national agencies have recommended monitoring antibacterial use and linking patterns of use to resistance,” the authors write.
Amy L. Pakyz, Pharm.D., M.S., of Virginia Commonwealth University, Richmond, and colleagues measured antibiotic use documented in claims data from university teaching hospitals between 2002 and 2006. In 2006 and 2007, pharmacists or physicians specializing in infectious diseases at 19 hospitals completed a 12-question survey about factors that may influence antimicrobial drug use, including whether the hospital had a stewardship program to reduce antibiotic use.
Data were available from 35 hospitals in 2006-that year, a total of 775,731 patients were discharged, with 492,721 (63.5 percent) receiving an antibacterial drug. Between 2002 and 2006, the average total antibacterial use at the 22 hospitals providing five-year data increased from 798 days of therapy per every 1,000 days patients were in the hospital to 855 per 1,000 patient-days in 2006.
When antibiotic use was examined by class, fluoroquinolones were the most commonly used, and their use remained constant. Five broad-spectrum antibiotic classes-those that act against a wide range of bacteria-increased significantly, driving the overall increase. “The other change contributing to the increase in total use was the marked increase in the use of vancomycin,” the authors write. “During five years, the mean [average] vancomycin use increased by 43 percent,” and this drug became the single most commonly used antibacterial in the hospitals studied between 2004 and 2006.
“With few new antibacterials in development, antimicrobial stewardship programs in concert with aggressive infection control efforts represent the best chance for control of resistant pathogens,” the authors write. “Stopping antibacterials when they are not needed, switching to more narrow-spectrum drug regimens and optimal dosing using pharmacokinetic and pharmacodynamic principles [interactions between drugs and the body] are critical. Equally important will be investigations designed to identify shorter durations of antibacterial treatments for nosocomial [hospital-acquired] infections that have the potential to dramatically decrease antibacterial exposure.”
Rates of antibiotic-resistant head and neck infections increased in pediatric patients nationwide between 2001 and 2006, according to a report in the January issue of Archives of Otolaryngology-Head & Neck Surgery. Before the 1980s, infections with strains of the bacteria Staphylococcus aureus resistant to the antibiotic methicillin (methicillin-resistant Staphylococcus aureus, or MRSA) were most often
Full Post: MRSA head and neck infections increase among children
Although infection control has been substantially ramped up in Canadian hospitals since the SARS crisis of 2003, the number of resistant bacterial infections post-SARS have multiplied even faster, a new Queen’s University study shows. Led by Queen’s epidemiologist Dr. Dick Zoutman, the national survey is a six-year follow-up to a study that was undertaken in
Full Post: Superbugs on the rise in Canadian hospitals
Targanta Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the November 19, 2008 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. AIDAC will review Targanta’s New Drug Application (NDA) for oritavancin for the treatment of complicated skin and skin structure infection (cSSSI) caused by gram-positive
Full Post: Targanta Therapeutics announces posting of briefing documents for review of FDA
Administering antibiotics as a preventive measure to patients in intensive care units (ICUs) increases their chances of survival. This has emerged from a study involving nearly sixthousand Dutch patients in thirteen hospitals. Researchers at University Medical Center (UMC) Utrecht have published their findings in an article in The New England Journal of Medicine. During the
Full Post: Fewer deaths with preventive antibiotic use
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a novel pathway for potential human exposure to antibiotic-resistant bacteria from intensively raised poultry-driving behind the trucks transporting broiler chickens from farm to slaughterhouse. A study by the Hopkins researchers found increased levels of pathogenic bacteria, both susceptible and drug-resistant, on
Full Post: Study looks at exposure to antibiotic-resistant bacteria from transportation of poultry